Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials

by Donald M. Jensen, Tarik Asselah, Douglas Dieterich, Graham R. Foster, Mark S. Sulkowski, Stefan Zeuzem, Parvez Mantry, Eric M. Yoshida, Christophe Moreno, Denis Ouzan, Mark Wright, Luis E. Morano, Robert Buynak, Marc Bourlière, Tarek Hassanein, Shuhei Nishiguchi, Jia-Horng Kao, Masao Omata, Seung W. Paik, David K. Wong, Edward Tam, Kelly Kaita, S. Victor Feinman, Jerry O. Stern, Joseph Scherer, Anne-Marie Quinson, Florian Voss, John-Paul Gallivan, Wulf O. Böcher, Peter Ferenci
Published 2016-05-01

Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb tri...

by M. Moehler, J. Heo, H.C. Lee, W.Y. Tak, Y. Chao, S.W. Paik, H.J. Yim, K.S. Byun, A. Baron, G. Ungerechts, D. Jonker, L. Ruo, M. Cho, A. Kaubisch, H. Wege, P. Merle, O. Ebert, F. Habersetzer, J.F. Blanc, Olivier Rosmorduc, R. Lencioni, R. Patt, A.M. Leen, F. Foerster, M. Homerin, N. Stojkowitz, M. Lusky, J.M. Limacher, M. Hennequi, N. Gaspar, B. McFadden, N. De Silva, D. Shen, A. Pelusio, D.H. Kirn, C.J. Breitbach, J.M. Burke
Published 2019-08-01